Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Neuroimmunol. 2004 Jun;151(1-2):55-65.

Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis.

Author information

  • 1Department of Neuroscience and Biomedical Technologies, University of Milan Bicocca, and Department of Neurology, S. Gerardo Hospital, Monza, Italy. guido.cavaletti@unimib.it

Abstract

Pixantrone is less cardiotoxic and is similarly effective to mitoxantrone (MTX) as an antineoplastic drug. In our study, pixantrone reduced the severity of acute and decreased the relapse rate of chronic relapsing experimental allergic encephalomyelitis (EAE) in rats. A marked and long-lasting decrease in CD3+, CD4+, CD8+ and CD45RA+ blood cells and reduced anti-MBP titers were observed with both pixantrone and MTX. In vitro mitogen- and antigen-induced T-cell proliferation tests of human and rodents cells evidenced that pixantrone was effective at concentrations which can be effectively obtained after i.v. administration in humans. Cardiotoxicity was present only in MTX-treated rats. The effectiveness and the favorable safety profile makes pixantrone a most promising immunosuppressant agent for clinical use in multiple sclerosis (MS).

PMID:
15145604
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk